Skip to main
NRXP
NRXP logo

NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals (NRXP) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NRX Pharmaceuticals Inc has bolstered its financial standing through recent financing activities, which have strengthened its cash position and facilitated ongoing development efforts in its therapeutic initiatives. The company is poised to achieve profitability on a run-rate basis by the end of 2025, supported by a robust clinical pipeline and expansion of its HOPE Therapeutics platform, which is anticipated to generate approximately $10 million in annual revenue from upcoming acquisitions. Additionally, positive clinical trial outcomes for NRX-101 enhance the company's outlook, potentially placing it as a leading treatment option for bipolar depression associated with acute suicidality, thereby reinforcing the company's target of achieving $100 million in revenue by 2025.

Bears say

NRX Pharmaceuticals Inc. is aiming to reduce its operating loss for 2024 to $18.5 million from the previous year's loss of $27.8 million, primarily through decreased research and development expenditures following the completion of the Phase 2b/3 study of NRX-101. The company faces significant risks, including the potential failure of clinical trials, the necessity for further regulatory studies, and challenges in its commercialization strategy that could hinder product launches and competitive positioning. Additionally, concerns about intellectual property, market conditions for fundraising, and the overall viability of its therapeutic developments contribute to a negative outlook on the stock.

NRX Pharmaceuticals (NRXP) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NRX Pharmaceuticals (NRXP) Forecast

Analysts have given NRX Pharmaceuticals (NRXP) a Strong Buy based on their latest research and market trends.

According to 5 analysts, NRX Pharmaceuticals (NRXP) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NRX Pharmaceuticals (NRXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.